Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial -

Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Information type: Randomised controlled trials
Source: JAMA Neurology
Specialities: Neurological disorders
Summary
This RCT (n=1671) reports treatment with sc galcanezumab once per month significantly reduced monthly migraine headache days by 4.7 days for patients on the 120mg dose and 4.6 days for those on 240mg vs 2.8 days for placebo (both P < 0.001).
UKMi comment

Galcanezumab is a humanised monoclonal antibody that selectively binds to and inhibits the activity of calcitonin gene-related peptide (CGRP). A marketing authorisation application has been filed with the European Medicines Agency.
Related links: